Is autophagy rather than apoptosis the regression driver in imatinib-treated gastrointestinal stromal tumors?

Translational Oncology

Volumn 1, Issue 4, 2008, Pages 177-186

  Miselli, Francesca ^a   Negri, Tiziana ^a   Gronchi, Alessandro ^a   Losa, Marco ^a   Conca, Elena ^a   Brich, Silvia ^a   Fumagalli, Elena ^a   Fiore, Marco ^a   Casali, Paolo G ^a   Pierotti, Marco A ^a   Tamborini, Elena ^a   Pilotti, Silvana ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 67650956613     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.08157     Document Type: Article

References (39)

1. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D, Singer S, Fletcher CD, Demetri GD, and Fletcher JA (2004). Mechanisms of oncogenicKIT signal transduction in primary gastrointestinal stromal tumors (GISTs). Oncogene 23, 3999-4006.
2. Bauer S, Duensing A, Demetri GD, and Fletcher JA (2007). KIT on cogenicsignaling mechanisms in imatinib-resistant gastrointestinal stromal tumor:PI3-kinase/AKT is a crucial survival pathway. Oncogene 26, 7560-7568.
3. Miselli FC, Casieri P, Negri T, Orsenigo M, Lagonigro MS, Gronchi A, Fiore M, Casali PG, Bertulli R, Carbone A, et al. (2007). c-Kit/PDGFRA gene status alterationspossibly related to primary imatinib resistance in gastrointestinal stromaltumors. Clin Cancer Res 13, 2369-2377.
4. Agaram NP, Besmer P, Wong GC, Guo T, Socci ND, Maki RG, DeSantis D, Brennan MF, Singer S, DeMatteo RP, et al. (2007). Pathologic and molecularheterogeneity in imatinib-stable or imatinib-responsive gastrointestinal stromaltumors. Clin Cancer Res 13, 170-181.
5. Miettinen M, Sobin LH, and Lasota J (2005). Gastrointestinal stromal tumorsof the stomach: a clinicopathologic, immunohistochemical, and molecular geneticstudy of 1765 cases with long-term follow-up. Am J Surg Pathol 29, 52-68.
6. Klionsky DJ and Emr SD (2000). Autophagy as a regulated pathway of cellulardegradation. Science 290, 1717-1721.
7. Gozuacik D and Kimchi A (2004). Autophagy as a cell death and tumor suppressormechanism. Oncogene 23, 2891-2906.
8. Maiuri MC, Zalckvar E, Kimchi A, and Kroemer G (2007). Self-eating and selfkilling:crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8, 741-752.
9. Levine B (2007). Cell biology: autophagy and cancer. Nature 446, 745-747.
10. Tsujimoto Y and Shimizu S (2005). Another way to die: autophagic programmedcell death. Cell Death Differ 12, 1528-1534.
11. Liang XH, Jackson S, Seaman M, Brown K, Kempkes B, Hibshoosh H, andLevine B (1999). Induction of autophagy and inhibition of tumorigenesis bybeclin 1. Nature 402, 672-676.
12. Yue Z, Jin S, Yang C, Levine AJ, and Heintz N (2003). Beclin 1, an autophagygene essential for early embryonic development, is a haploinsufficient tumorsuppressor. Proc Natl Acad Sci USA 100, 15077-15082.
13. Kihara A, Kabeya Y, Ohsumi Y, and Yoshimori T (2001). Beclin-phosphatidylinositol3-kinase complex functions at the trans-Golgi network. EMBO Rep 2, 330-335.
14. Zeng X, Overmeyer JH, and Maltese WA (2006). Functional specificity of themammalian Beclin-Vps34 PI 3-kinase complex in macroautophagy versus endocytosisand lysosomal enzyme trafficking. J Cell Sci 119, 259-270.
15. Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Schneider MD, and Levine B (2005). Bcl-2 antiapoptotic proteins inhibit Beclin1-dependent autophagy. Cell 122, 927-939.
16. Pattingre S and Levine B (2006). Bcl-2 inhibition of autophagy: a new route tocancer? Cancer Res 66, 2885-2888.
17. Mizushima N and Yoshimori T (2007). How to interpret LC3 immunoblotting. Autophagy 3, 542-545.
18. Kondo Yand Kondo S (2006). Autophagy and cancer therapy. Autophagy 2, 85-90.
19. Gronchi A, Fiore M, Miselli F, Lagonigro MS, Coco P, Messina A, Pilotti S, andCasali PG (2007). Surgery of residual disease following molecular-targetedtherapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 245, 341-346.
20. Perrone F, Tamborini E, Dagrada GP, Colombo F, Bonadiman L, Albertini V, Lagonigro MS, Gabanti E, Caramuta S, Greco A, et al. (2005). 9p21 locus analysisin high-risk gastrointestinal stromal tumors characterized for c-kit and plateletderivedgrowth factor receptor alpha gene alterations. Cancer 104, 159-169.
21. Benjamin RS, Choi H, Macapinlac HA, Burgess MA, Patel SR, Chen LL, Podoloff DA, and Charnsangavej C (2007). We should desist using RECIST, at least in GIST. J Clin Oncol 25, 1760-1764.
22. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. (2000). New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Instituteof the United States, National Cancer Institute of Canada. J Nat Cancer Inst 92, 205-216.
23. Heinrich MC, Corless CL, Blanke CD, Demetri GD, Joensuu H, Roberts PJ, Eisenberg BL, von Mehren M, Fletcher CD, Sandau K, et al. (2006). Molecularcorrelates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol24, 4764-4774.
24. Lagonigro MS, Tamborini E, Negri T, Staurengo S, Dagrada GP, Miselli F, Gabanti E, Greco A, Casali PG, Carbone A, et al. (2006). PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. J Pathol 208, 615-623.
25. Lassar AB, Davis RL, Wright WE, Kadesch T, Murre C, Voronova A, Baltimore D, and Weintraub H (1991). Functional activity of myogenic HLH proteinsrequires hetero-oligomerization with E12/E47-like proteins in vivo. Cell 66, 305-315.
26. Yantiss RK, Spiro IJ, Compton CC, and Rosenberg AE (2000). Gastrointestinalstromal tumor versus intra-abdominal fibromatosis of the bowel wall: a clinicallyimportant differential diagnosis. Am J Surg Pathol 24, 947-957.
27. Steinert DM, Oyarzo M, Wang X, Choi H, Thall PF, Medeiros LJ, Raymond AK, Benjamin RS, Zhang W, and Trent JC (2006). Expression of Bcl-2 in gastrointestinalstromal tumors: correlation with progression-free survival in 81 patientstreated with imatinib mesylate. Cancer 106, 1617-1623.
28. Ertmer A, Huber V, Gilch S, Yoshimori T, Erfle V, Duyster J, Elsässer HP, andSchätzl HM (2007). The anticancer drug imatinib induces cellular autophagy. Leukemia 21, 936-942.
29. Lockshin RA and Zakeri Z (2004). Apoptosis, autophagy, and more. Int J BiochemCell Biol 36, 2405-2419.
30. Mizushima N, Levine B, Curevo AM, and Klionsky AJ (2008). Autophagyfights disease through cellular self-digestion. Nature 451, 1069-1075.
31. Akar U, Chaves-Reyes A, Barria M, Tari A, Saungino A, Kondo Y, Kondo S, Arun B, Lopez-Berestein G, and Ozpolat B (2008). Silencing of Bcl-2 expressionby small interfering RNA induces autophagic cell death in MCF-7 breastcancer cells. Autophagy 4 (5) [Epub ahead of print].
32. Rubin BP (2006). Gastrointestinal stromal tumours: an update. Histopathology48, 83-96.
33. Weiss SW and Goldblum JR. Extragastrointestinal stromal tumors. In Enzingerand Weiss's Soft Tissue Tumours. Mosby Elsevier, 5th ed. pp. 565-581.
34. Bergmann A (2007). Autophagy and cell death: no longer at odds. Cell 13, 1032-1033.
35. Sambol EB, Ambrosini G, Geha RC, Kennealey PT, Decarolis P, O'connor R, Wu YV, Motwani M, Chen JH, Schwartz GK, et al. (2006). Flavopiridol targetsc-KIT transcription and induces apoptosis in gastrointestinal stromal tumorcells. Cancer Res 66, 5858-5866.
36. Frolov A, Chahwan S, Ochs M, Arnoletti JP, Pan ZZ, Favorova O, Fletcher J, vonMehren M, Eisenberg B, and Godwin AK (2003). Response markers and themolecular mechanisms of action of Gleevec in gastrointestinal stromal tumors. Mol Cancer Ther 2, 699-709.
37. Takeuchi H, Kondo Y, Fujiwara K, Kanzawa T, Aoki H, Mills GB, and Kondo S (2005). Synergistic augmentation of rapamycin-induced autophagy in malignantglioma cells by phosphatidylinositol 3-kinase/protein kinase B inhibitors. CancerRes 65, 3336-3346.
38. Pattingre S, Bauvy C, and Codogno P (2003). Amino acids interfere with theERK1/2-dependent control of macroautophagy by controlling the activation ofRaf-1 in human colon cancer HT-29 cells. J Biol Chem 278, 16667-16674.
39. Aoki H, Takada Y, Kondo S, Sawaya R, Aggarwal BB, and Kondo Y (2007). Evidence that curcumin suppresses the growth of malignant gliomas in vitro andin vivo through induction of autophagy: role of Akt and extracellular signalregulatedkinase signaling pathways. Mol Pharmacol 72, 29-33.